非小细胞肺癌中ROS1融合罕见与其他致癌驱动基因共存
研究在62例ROS1重排NSCLC患者中未发现ALK融合或EGFR激活突变,KRAS突变仅2例(3.2%);FoundationOne独立数据集166例中EGFR共存1例、KRAS共存3例,无ROS1与ALK共存。结论认为ROS1重排罕与其他可靶向致癌基因共存。
要点
- 本机构62例ROS1重排NSCLC中无ALK融合(0%)和EGFR激活突变(0%)。
- 本机构队列KRAS突变2例(3.2%),其中1例为非经典KRAS I24N。
- FoundationOne数据集166例中EGFR共存1例、KRAS共存3例,无ALK共存。
核心结论
- 非小细胞肺癌中ROS1重排罕见与EGFR、KRAS、ALK或其他可靶向致癌基因改变共存。
研究设计与样本
- 研究纳入本机构62例ROS1重排NSCLC患者,并回顾其EGFR、KRAS和ALK等基因检测结果及临床病理特征。
- 另分析FoundationOne商业检测识别的166例ROS1重排NSCLC独立数据集。
主要发现
- 本机构62例中无ALK融合(0%)和EGFR激活突变(0%),KRAS突变2例(3.2%)。
- KRAS突变2例中1例携带非经典KRAS I24N突变,生物学意义未知。
- 另1例ROS1 FISH阳性病例靶向测序未确认ROS1融合,检出KRAS G13D突变。
- 未检出BRAF、ERBB2、PIK3CA、AKT1或MAP2K1共存突变。
- FoundationOne数据集166例中EGFR共存1例、KRAS共存3例,无ROS1与ALK重排共存。
关键数值与推荐
- 本机构队列ROS1重排NSCLC患者62例,ALK融合0%(0/62),EGFR激活突变0%(0/62)。
- 本机构队列KRAS突变3.2%(2/62)。
- FoundationOne数据集ROS1重排NSCLC 166例,EGFR共存1/166,KRAS共存3/166,ALK共存0/166。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chromosomal rearrangements involving the gene ROS1 define a distinct molecular subset of NSCLCs with sensitivity to ROS1 inhibitors. Recent reports have suggested a significant overlap between ROS1 fusions and other oncogenic driver alterations, including mutations in EGFR and KRAS. METHODS: We identified patients at our institution with ROS1-rearranged NSCLC who had undergone testing for genetic alterations in additional oncogenes, including EGFR, KRAS, and anaplastic lymphoma receptor tyrosine kinase gene (ALK). Clinicopathologic features and genetic testing results were reviewed. We also examined a separate database of ROS1-rearranged NSCLCs identified through the commercial FoundationOne assay (Foundation Medicine, Cambridge, MA). RESULTS: Among 62 patients with ROS1-rearranged NSCLC evaluated at our institution, none harbored concurrent ALK fusions (0%) or EGFR activating mutations (0%). KRAS mutations were detected in two cases (3.2%), one of which harbored a concurrent noncanonical KRAS I24N mutation of unknown biological significance. In a separate ROS1 fluorescence in situ hybridization-positive case, targeted sequencing failed to confirm a ROS1 fusion but instead identified a KRAS G13D mutation. No concurrent mutations in B-Raf proto-oncogene, serine/threonine kinase gene (BRAF), erb-b2 receptor tyrosine kinase 2 gene (ERBB2), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA), AKT/serine threonine kinase 1 gene (AKT1), or mitogen-activated protein kinase kinase 1 gene (MAP2K1) were detected. Analysis of an independent data set of 166 ROS1-rearranged NSCLCs identified by FoundationOne demonstrated rare cases with co-occurring driver mutations in EGFR (one of 166) and KRAS (three of 166) and no cases with co-occurring ROS1 and ALK rearrangements. CONCLUSIONS: ROS1 rearrangements rarely overlap with alterations in EGFR, KRAS, ALK, or other targetable oncogenes in NSCLC.
引用
- Lin JJ, Ritterhouse LL, Ali SM, et al. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28088512. doi:10.1016/j.jtho.2017.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。